Cite
HARVARD Citation
Essink, B. et al. (2022). Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years. Clinical infectious diseases. pp. 390-398. [Online].